Cholinergic enhancement of frontal lobe activity in mild cognitive impairment

Andrew Saykin, Heather A. Wishart, Laura A. Rabin, Laura A. Flashman, Tara L. McHugh, Alexander C. Mamourian, Robert B. Santulli

Research output: Contribution to journalArticle

173 Citations (Scopus)

Abstract

Cholinesterase inhibitors positively affect cognition in Alzheimer's disease (AD) and other conditions, but no controlled functional MRI studies have examined where their effects occur in the brain. We examined the effects of donepezil hydrochloride (Aricept®) on cognition and brain activity in patients with amnestic mild cognitive impairment (MCI), a diagnosis associated with a high risk of developing AD. Nine older adults with MCI were compared with nine healthy, demographically matched controls. At baseline, patients showed reduced activation of frontoparietal regions relative to controls during a working memory task. After stabilization on donepezil (5.7 ± 1.7 weeks at 10 mg) patients showed increased frontal activity relative to unmedicated controls, which was positively correlated with improvement in task performance (r = 0.49, P = 0.05) as well as baseline hippocampal volume (r = 0.62, P <0.05). The patients' overall cognitive function was stable or improved throughout the study. Short-term treatment with a cholinesterase inhibitor appears to enhance the activity of frontal circuitry in patients with MCI, and this increase appears to be related to improved cognition and to baseline integrity of the hippocampus. These relationships have implications for understanding the mechanisms by which cognition-enhancing medications exert their effects on brain function and for the use of functional MRI in early detection and treatment monitoring of AD and MCI.

Original languageEnglish (US)
Pages (from-to)1574-1583
Number of pages10
JournalBrain
Volume127
Issue number7
DOIs
StatePublished - Jul 2004
Externally publishedYes

Fingerprint

Frontal Lobe
Cognition
Cholinergic Agents
Alzheimer Disease
Cholinesterase Inhibitors
Brain
Magnetic Resonance Imaging
Task Performance and Analysis
Short-Term Memory
Hippocampus
Cognitive Dysfunction
Therapeutics
donepezil

Keywords

  • Alzheimer's disease
  • Cholinesterase inhibitor
  • Functional MRI
  • Hippocampal volume
  • Mild cognitive impairment

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Saykin, A., Wishart, H. A., Rabin, L. A., Flashman, L. A., McHugh, T. L., Mamourian, A. C., & Santulli, R. B. (2004). Cholinergic enhancement of frontal lobe activity in mild cognitive impairment. Brain, 127(7), 1574-1583. https://doi.org/10.1093/brain/awh177

Cholinergic enhancement of frontal lobe activity in mild cognitive impairment. / Saykin, Andrew; Wishart, Heather A.; Rabin, Laura A.; Flashman, Laura A.; McHugh, Tara L.; Mamourian, Alexander C.; Santulli, Robert B.

In: Brain, Vol. 127, No. 7, 07.2004, p. 1574-1583.

Research output: Contribution to journalArticle

Saykin, A, Wishart, HA, Rabin, LA, Flashman, LA, McHugh, TL, Mamourian, AC & Santulli, RB 2004, 'Cholinergic enhancement of frontal lobe activity in mild cognitive impairment', Brain, vol. 127, no. 7, pp. 1574-1583. https://doi.org/10.1093/brain/awh177
Saykin A, Wishart HA, Rabin LA, Flashman LA, McHugh TL, Mamourian AC et al. Cholinergic enhancement of frontal lobe activity in mild cognitive impairment. Brain. 2004 Jul;127(7):1574-1583. https://doi.org/10.1093/brain/awh177
Saykin, Andrew ; Wishart, Heather A. ; Rabin, Laura A. ; Flashman, Laura A. ; McHugh, Tara L. ; Mamourian, Alexander C. ; Santulli, Robert B. / Cholinergic enhancement of frontal lobe activity in mild cognitive impairment. In: Brain. 2004 ; Vol. 127, No. 7. pp. 1574-1583.
@article{7017f3da738e489eb6386bdf61dc962c,
title = "Cholinergic enhancement of frontal lobe activity in mild cognitive impairment",
abstract = "Cholinesterase inhibitors positively affect cognition in Alzheimer's disease (AD) and other conditions, but no controlled functional MRI studies have examined where their effects occur in the brain. We examined the effects of donepezil hydrochloride (Aricept{\circledR}) on cognition and brain activity in patients with amnestic mild cognitive impairment (MCI), a diagnosis associated with a high risk of developing AD. Nine older adults with MCI were compared with nine healthy, demographically matched controls. At baseline, patients showed reduced activation of frontoparietal regions relative to controls during a working memory task. After stabilization on donepezil (5.7 ± 1.7 weeks at 10 mg) patients showed increased frontal activity relative to unmedicated controls, which was positively correlated with improvement in task performance (r = 0.49, P = 0.05) as well as baseline hippocampal volume (r = 0.62, P <0.05). The patients' overall cognitive function was stable or improved throughout the study. Short-term treatment with a cholinesterase inhibitor appears to enhance the activity of frontal circuitry in patients with MCI, and this increase appears to be related to improved cognition and to baseline integrity of the hippocampus. These relationships have implications for understanding the mechanisms by which cognition-enhancing medications exert their effects on brain function and for the use of functional MRI in early detection and treatment monitoring of AD and MCI.",
keywords = "Alzheimer's disease, Cholinesterase inhibitor, Functional MRI, Hippocampal volume, Mild cognitive impairment",
author = "Andrew Saykin and Wishart, {Heather A.} and Rabin, {Laura A.} and Flashman, {Laura A.} and McHugh, {Tara L.} and Mamourian, {Alexander C.} and Santulli, {Robert B.}",
year = "2004",
month = "7",
doi = "10.1093/brain/awh177",
language = "English (US)",
volume = "127",
pages = "1574--1583",
journal = "Brain",
issn = "0006-8950",
publisher = "Oxford University Press",
number = "7",

}

TY - JOUR

T1 - Cholinergic enhancement of frontal lobe activity in mild cognitive impairment

AU - Saykin, Andrew

AU - Wishart, Heather A.

AU - Rabin, Laura A.

AU - Flashman, Laura A.

AU - McHugh, Tara L.

AU - Mamourian, Alexander C.

AU - Santulli, Robert B.

PY - 2004/7

Y1 - 2004/7

N2 - Cholinesterase inhibitors positively affect cognition in Alzheimer's disease (AD) and other conditions, but no controlled functional MRI studies have examined where their effects occur in the brain. We examined the effects of donepezil hydrochloride (Aricept®) on cognition and brain activity in patients with amnestic mild cognitive impairment (MCI), a diagnosis associated with a high risk of developing AD. Nine older adults with MCI were compared with nine healthy, demographically matched controls. At baseline, patients showed reduced activation of frontoparietal regions relative to controls during a working memory task. After stabilization on donepezil (5.7 ± 1.7 weeks at 10 mg) patients showed increased frontal activity relative to unmedicated controls, which was positively correlated with improvement in task performance (r = 0.49, P = 0.05) as well as baseline hippocampal volume (r = 0.62, P <0.05). The patients' overall cognitive function was stable or improved throughout the study. Short-term treatment with a cholinesterase inhibitor appears to enhance the activity of frontal circuitry in patients with MCI, and this increase appears to be related to improved cognition and to baseline integrity of the hippocampus. These relationships have implications for understanding the mechanisms by which cognition-enhancing medications exert their effects on brain function and for the use of functional MRI in early detection and treatment monitoring of AD and MCI.

AB - Cholinesterase inhibitors positively affect cognition in Alzheimer's disease (AD) and other conditions, but no controlled functional MRI studies have examined where their effects occur in the brain. We examined the effects of donepezil hydrochloride (Aricept®) on cognition and brain activity in patients with amnestic mild cognitive impairment (MCI), a diagnosis associated with a high risk of developing AD. Nine older adults with MCI were compared with nine healthy, demographically matched controls. At baseline, patients showed reduced activation of frontoparietal regions relative to controls during a working memory task. After stabilization on donepezil (5.7 ± 1.7 weeks at 10 mg) patients showed increased frontal activity relative to unmedicated controls, which was positively correlated with improvement in task performance (r = 0.49, P = 0.05) as well as baseline hippocampal volume (r = 0.62, P <0.05). The patients' overall cognitive function was stable or improved throughout the study. Short-term treatment with a cholinesterase inhibitor appears to enhance the activity of frontal circuitry in patients with MCI, and this increase appears to be related to improved cognition and to baseline integrity of the hippocampus. These relationships have implications for understanding the mechanisms by which cognition-enhancing medications exert their effects on brain function and for the use of functional MRI in early detection and treatment monitoring of AD and MCI.

KW - Alzheimer's disease

KW - Cholinesterase inhibitor

KW - Functional MRI

KW - Hippocampal volume

KW - Mild cognitive impairment

UR - http://www.scopus.com/inward/record.url?scp=3142547230&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3142547230&partnerID=8YFLogxK

U2 - 10.1093/brain/awh177

DO - 10.1093/brain/awh177

M3 - Article

C2 - 15140813

AN - SCOPUS:3142547230

VL - 127

SP - 1574

EP - 1583

JO - Brain

JF - Brain

SN - 0006-8950

IS - 7

ER -